Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & Neck Cancer.

IF 0.7 Q4 SURGERY

Current Surgery Reports Pub Date : 2024-01-01 Epub Date: 2024-02-28 DOI:10.1007/s40137-024-00386-z

Sarah Anne Wong, Victoria A Manon, Simon Young, Chi T Viet

{"title":"Innovations in Molecular Biomarkers and Biomaterial-Based Immunotherapies for Head & Neck Cancer.","authors":"Sarah Anne Wong, Victoria A Manon, Simon Young, Chi T Viet","doi":"10.1007/s40137-024-00386-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: Oral squamous cell carcinoma (OSCC) survival rates have remained stagnant due to a lack of targeted therapies and diagnostic tools. Patient risk is currently determined solely through clinicopathologic features, primarily tumor staging, which lacks the necessary precision to stratify patients by risk and accurately dictate adjuvant treatment. Similarly, conventional OSCC therapies have well-established toxicities and limited efficacy.Recent findings: Recent studies show that patient risk can now be assessed using non-invasive techniques, at earlier time points, and with greater accuracy using molecular biomarker panels. Additionally, novel immunotherapies not only utilize the host's immune response to combat disease but also have the potential to form immunological memory to prevent future recurrence. Localized controlled-release formulas have further served to reduce toxicity and allow the de-escalation of other treatment modalities.Summary: We review the latest advances in head and neck cancer diagnosis and treatment, including novel molecular biomarkers and immunotherapies.","PeriodicalId":44090,"journal":{"name":"Current Surgery Reports","volume":"12 4","pages":"45-51"},"PeriodicalIF":0.7000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10954983/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Surgery Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40137-024-00386-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Oral squamous cell carcinoma (OSCC) survival rates have remained stagnant due to a lack of targeted therapies and diagnostic tools. Patient risk is currently determined solely through clinicopathologic features, primarily tumor staging, which lacks the necessary precision to stratify patients by risk and accurately dictate adjuvant treatment. Similarly, conventional OSCC therapies have well-established toxicities and limited efficacy.

Recent findings: Recent studies show that patient risk can now be assessed using non-invasive techniques, at earlier time points, and with greater accuracy using molecular biomarker panels. Additionally, novel immunotherapies not only utilize the host's immune response to combat disease but also have the potential to form immunological memory to prevent future recurrence. Localized controlled-release formulas have further served to reduce toxicity and allow the de-escalation of other treatment modalities.

Summary: We review the latest advances in head and neck cancer diagnosis and treatment, including novel molecular biomarkers and immunotherapies.

查看原文本刊更多论文

头颈癌分子生物标志物和基于生物材料的免疫疗法的创新。

综述目的：由于缺乏靶向疗法和诊断工具，口腔鳞状细胞癌（OSCC）的存活率一直停滞不前。目前，患者的风险仅通过临床病理特征（主要是肿瘤分期）来确定，缺乏必要的精确性来对患者进行风险分层并准确决定辅助治疗。同样，传统的OSCC疗法也有公认的毒性和有限的疗效：最近的研究表明，现在可以使用非侵入性技术，在更早的时间点，利用分子生物标记物面板更准确地评估患者的风险。此外，新型免疫疗法不仅能利用宿主的免疫反应来对抗疾病，还有可能形成免疫记忆，防止未来复发。总结：我们回顾了头颈癌诊断和治疗的最新进展，包括新型分子生物标记物和免疫疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Surgery Reports SURGERY-

CiteScore

1.00

自引率

0.00%

发文量

期刊介绍： This journal aims to offer expert review articles on the most significant recent developments in the field of surgery. By providing clear, insightful, balanced contributions, the journal intends to serve those for whom the elucidation of novel surgical techniques and related technologies is essential. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include bariatric surgery; CT screening; endovascular treatment of complex vasculopathies; minimally invasive surgery; natural orifice surgery; and transplantation.